NCT04926051View on ClinicalTrials.gov

A Study to Assess the Safety, Tolerability and Drug Levels of BMS-986172 in Healthy and Obese Participants, Including an Assessment of the Effects of Food on BMS-986172 Absorption

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 15, 2021

Primary Completion Date

December 28, 2021

Study Completion Date

December 28, 2021

Conditions
Healthy Participants
Interventions
DRUG

BMS-986172

Specified dose on specified days

OTHER

Placebo

Specified dose on specified days

Trial Locations (1)

66215

ICON Plc (Legacy PRA), Lenexa

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT04926051 - A Study to Assess the Safety, Tolerability and Drug Levels of BMS-986172 in Healthy and Obese Participants, Including an Assessment of the Effects of Food on BMS-986172 Absorption | Biotech Hunter | Biotech Hunter